John Grundy Selected Research

ralinepag

10/2019

Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John Grundy Research Topics

Disease

2	Infections 01/2017 - 04/2009
1	Hypertension (High Blood Pressure) 01/2021
1	Stroke (Strokes) 01/2021
1	Obesity 01/2021
1	Pulmonary Arterial Hypertension 10/2019
1	Chronic Hepatitis C 01/2017
1	Japanese Encephalitis 04/2009
1	Meningoencephalitis 04/2009
1	Leiomyoma (Uterine Fibroids) 02/2009
1	Endometriosis 02/2009

Drug/Important Bio-Agent (IBA)

1	CholesterolIBA 01/2021
1	ralinepagIBA 10/2019
1	ProstaglandinsIBA 10/2019
1	Epoprostenol ReceptorsIBA 10/2019
1	AcetylgalactosamineIBA 01/2017
1	temavirsen sodiumIBA 01/2017
1	InterferonsIBA 01/2017
1	Antiviral Agents (Antivirals)IBA 01/2017
1	OligonucleotidesIBA 01/2017
1	VaccinesIBA 04/2009
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 02/2009
1	Peptides (Polypeptides)IBA 02/2009

Therapy/Procedure

2	Therapeutics 01/2017 - 02/2009